Xenon Pharmaceuticals Presents Data from Phase 2 X-NOVA Clinical Trial of Azetukalner in Major Depressive Disorder at the American Society of Clinical Psychopharmacology 2024 Annual Meeting

VANCOUVER, British Columbia, May 28, 2024 -- Xenon Pharmaceuticals Inc. , a neuroscience-focused biopharmaceutical company, announced data presentations highlighting azetukalner clinical data in...

Related Keywords

Canada ,United States ,Vancouver ,British Columbia ,Miami ,Florida ,United Kingdom ,Canadian ,American ,British ,Jodi Regts ,Joe Mcintosh ,Ian Mortimer ,Exchange Commission ,Clinical Development ,Securities Exchange ,American Society Of Clinical Psychopharmacology ,Xenon Pharmaceuticals Inc ,Xenon Corporate Affairs ,Nasdaq ,Xenon Pharmaceuticals Nasdaq ,Xenon Pharmaceuticals ,American Society ,Clinical Psychopharmacology ,Chief Executive Officer ,Channel Opener ,Adults With Moderate ,Severe Major Depressive Disorder ,Results From ,Senior Vice President ,Efficacy Data ,Depression Rating Scale ,Hamilton Depression Rating Scale ,Snaith Hamilton Pleasure Scale ,Clinical Global Impression ,Tolerability Data ,Securities Act ,Securities Exchange Act ,Private Securities Litigation Reform Act ,